Bio-Path net loss narrows 60.99% to $2.91 million in 1H FY26; no revenue
BPTH•First-half loss narrows as expenses fall
Bio-Path Holdings posted a GAAP net loss of $2.91 million, narrowing from $7.45 million a year earlier.
- Operating loss improved to $1.23 million from $7.8 million.
- Net loss per share narrowed to $0.15 from $0.97.
- Research and development expense fell to $916,000 from $6.03 million due to pausing BP1001 and BP1001-A clinical trials.
- General and administrative costs dropped to $318,000 from $1.78 million on lower overhead following 2025 workforce reductions.
- The company reported no revenue.
Board launches AI-driven digital asset treasury
The board launched an AI-driven digital asset treasury, opened a Coinbase business account, and said it intends to allocate up to 50% of raised capital to crypto.
